Sabinsa

ANVISA approves first tetrahydrocurcuminoid for use in Brazil

19-Jan-2024 By Asia Sherman

Natural ingredient supplier Sabinsa announced this week that The Brazilian Health Regulatory Agency (ANVISA) has green-lighted its Curcumin C3 Reduct as health ingredient in the country.

Sami-Sabinsa inaugurates new manufacturing facility for global growth

04-Apr-2023 By Asia Sherman

Sami-Sabinsa Group – parent company to nutraceutical health supplement and herbal extract supplier Sabinsa – inaugurated a new state-of-the-art manufacturing facility in the city of Hassan in southern India.

Sabinsa study elucidates blood sugar benefits of amla ingredient

13-Feb-2023 By Nikki Hancocks

Pharmaceutical corporation Sabinsa completed a 90 day, multicentric randomised open label trial of its Amla, aka Indian gooseberry, extract and concluded it could provide blood sugar benefits.

Sabinsa mourns passing of CEO V.G. Nair

07-Jul-2022

Dr. Muhammed Majeed, Sami-Sabinsa Group’s founder, Chairman, and Managing Director, has expressed his sadness at the death of the group’s CEO, V.G. Nair.

Novel Foods approval has “burnished the image” of curcuminoid ingredient

21-Feb-2022 By Lynda Searby

Sabinsa has secured Novel Food approval for its patented curcuminoid metabolite ingredient C3 Reduct, giving supplement manufacturers in Europe a bioavailable curcuminoid option.

PEOPLE ON THE MOVE

Industry Movers: Glanbia Nutritionals, Sabinsa & J&J

27-Sep-2021 By Will Chu

September 2021 and while the nights draw in and the temperature drops, opportunities in the food and nutrition sector remain red-hot as NutraIngredients features those seeking a new challenge.

Cardioprotective properties found in pterostilbene: Study

19-Nov-2019 By Danielle Masterson

Sabinsa researchers and academic scientists released a new study that links the polyphenol to heart health.

Clinical trial finds curcuminoids plus piperine improve non-alcoholic fatty liver disease

01-Nov-2019 By Danielle Masterson

The American Liver Foundation estimates at least 25% of the US population has nonalcoholic fatty liver disease, a condition in which excess fat is stored in your liver. NAFLD is the most common chronic liver condition and currently there are no approved...

Sabinsa concludes curcumin patent suit that was part of a series involving Indian suppliers

06-Jan-2016 By Hank Schultz

Sabinsa Corp. has prevailed in yet another patent infringement suit based on its Curcumin C3 Complex ingredient. The most recent settlement is one in a series of suits the company filed to defend its patents in this red-hot sector.

Sabinsa’s LactoSpore get Canadian approval

21-Jan-2015

Health Canada has reviewed and approved Sabinsa’s shelf-stable probiotic LactoSpore ingredient for sale in Canada.

Sabinsa rolls out novel Moringa and Boswellia extracts, hails ‘overwhelming response’ to Curcumin C3 Reduct

01-May-2013 By Stephen DANIELLS

Sabinsa Corporation is launching two novel water-soluble ingredients, one from of Boswellia serrata, called Polybos, and the other called MoringIn from Moringa oleifera.

Black pepper extract leader gains patent boost

18-Sep-2009 By Shane Starling

A US patent renewal recently handed to black pepper extract market leader, Sabinsa, is a warning shot to potential transgressors, the company that dominates the market for the thermogenic, bioavailability-improving extract, has said.

Sabinsa self-certifies Indian gooseberry as GRAS

23-Apr-2009 By Shane Starling

Sabinsa has achieved self-certification for its Amla ingredient, Saberry, after an independent panel of scientifists took no issue with its safety and toxicology data.

Sabinsa gets court approval for case against forskolin rival

03-Jan-2005

Sabinsa, maker of the forskolin weight loss supplement Forslean,
has gained court approval for its case against a Missouri company
marketing an extract of the Coleus forskohlii root under a similar
name.